Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?
Joline S.W. Lind(Amsterdam UMC Location Vrije Universiteit Amsterdam), Egbert F. Smit(Dutch Cancer Society), Martijn R. Meijerink(Amsterdam University Medical Centers), Cornelis van Kuijk(Amsterdam UMC Location VUmc), Michel Öllers(Maastricht University Medical Centre), Anne‐Marie C. Dingemans(Erasmus MC Cancer Institute), Dirk De Ruysscher(Maastricht University Medical Centre), Pieter E. Postmus(Leiden University Medical Center)
Cited by 84
Related Papers
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k
Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer
|New England Journal of Medicine|2007|1.1k
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|782
Prevalence and Characteristics of Nutritional Depletion in Patients with Stable COPD Eligible for Pulmonary Rehabilitation
|American Review of Respiratory Disease|1993|725